Scientific Abstracts

Abstract proposals on the study of the Prevalence, Comorbidities, Burden and QoL, or disparities across sleep wake disorders (SWD) or within individual SWD are encouraged to be submitted for poster presentation.

Areas of Specific Interest include:

Central Disorders of Hypersomnolence
Narcolepsy: Measurement or treatment of burden beyond pentad symptoms
Idiopathic Hypersomnia: Dysautonomias, brain fog and other comorbidities

Sleep Disordered Breathing
Sleep disordered breathing: Defining disease beyond the AHI
Sleep Disordered Breathing: Treatment alternatives to PAP

Sleep Wake Disorders
Sleep Duration or Timing: Which matter more
Psychological, social or behavioral considerations in SWD diagnosis and management

Future of Sleep
Sleep as a biomarker of wellness or development of disease
Innovation in sleep diagnostics

Scientific abstracts with no data and/or only a promise of future data will not be accepted. Scientific abstracts must contain the following:

1. A descriptive title, list of authors and institutions;
2. An introduction/rationale to the study;
3. The methods used;
4. The results of the study including new data not previously published or presented at a major national or international meeting;
5. Conclusions of the study. It is not satisfactory to state: "The results will be discussed."

Abstracts reporting the results of meta-analyses and systematic reviews will also be considered.

It is recommended that the abstract content be organized with the following headings: RATIONALE, METHODS, RESULTS, AND CONCLUSIONS.

SCIENTIFIC ABSTRACTS NOT MEETING THESE MINIMUM CRITERIA WILL NOT BE ACCEPTED.

Submission Fee

There is no submission fee for abstracts.

Language

The abstract must be submitted in English. If accepted, the abstract must be presented in English.

Prior Publication

Abstracts may be submitted for consideration if the work covered is to be published or presented at a major national or international meeting before the Sleep-Wake Advisor Summit. Abstracts of work presented at local or regional meetings may also be submitted for consideration.

Embargo Policy

We do not have an embargo policy

Research Funding Source

All abstracts must specify the funding source: i.e., pharmaceutical firm name, grant name, and source or other specific funding source. Compliance to this rule is a prerequisite for review. If you have no specific funding source, please indicate "none."

Authors

- The person submitting the abstract will automatically be the Presenting Author. The Presenting Author will be listed first.
- The submitter (Presenting Author) is responsible for ensuring that all co-authors have agreed to be listed on the abstract and have knowledge of the abstract submission.

Disclosure

The Presenting Author must complete the Release of Poster Presentation and Conflict of Interest Statement on the registration site and linked below.

Abstract Length

The total word count of an abstract may not exceed 500 words. Note: The 500-word count is for the abstract body (title, authors' information, institutions, tables, images and spaces between words will not count towards the 500-word count).

Accuracy

Responsibility for accuracy rests with the Presenting Author.

Abbreviations

When using abbreviations, spell the full name out on the first mention and follow with the abbreviation in parentheses. Do not abbreviate compounds in the title of the abstract. The use of unfamiliar abbreviations may be grounds for rejection unless definitions are supplied in the abstract.

Table/Graph/Image

A maximum of 2 Tables OR figures can be included per abstract in JPG format only. When including a table, it is recommended to save the table as an image and then upload it into the abstract body. The image will not count towards the 500-word count. Please note: If you choose to include a high-quality table or figure, make sure it is legible (for review and publication).

Abstract Review/Programming

- Abstracts that meet acceptable scientific and ethical standards and fulfill the above guidelines will be considered.

- The Conference Chairs reserve the right to reject abstracts based on failure to fulfill submission criteria, but also on relative merit and scheduling requirements of the Conference

After the abstract submission period closes, abstracts will be reviewed by the Sleep-Wake Advisor Summit Chairs in a blinded review. You will be notified if your abstract has been accepted for the poster gallery by September 30, 2025.

Presentations

Should your abstract be selected, your electronic poster will be displayed in a virtual poster gallery "room" as part of the platform of the **2025** *Approaches to Implementing Optimal Practice Strategies* will be available for participants to view throughout the

entire conference. You will be asked to submit a poster depicting the components of your abstract and a short video description of your project highlighting sections of the poster.

During the meeting, the Chairs will discuss select posters, including displaying your video segments. You do not have to stay for the poster discussions during the conference. Please provide a contact email address on the poster in case learners have follow-up questions.

Gold, Silver, and Bronze recognition awards will be given to the four most outstanding posters.

More details about how to prepare your poster will be provided in your letter of acceptance.

Publication

All accepted posters, with the video recordings, will be published in the Sleep-Wake Advisor Institute and made available for 3 months after the conference.

Submit abstracts to Debbie.Gaito@haymarketmedical.com. Abstracts will be accepted until **August 1, 2025**.

IMPORTANT: You must also submit a completed conflict of interest and poster release form at the time of abstract submission. **Download this Word form**.